PRIME MEDICINE INC (PRME) Fundamental Analysis & Valuation

NASDAQ:PRME • US74168J1016

Current stock price

3.38 USD
-0.26 (-7.14%)
At close:
3.3646 USD
-0.02 (-0.46%)
After Hours:

This PRME fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PRME Profitability Analysis

1.1 Basic Checks

  • In the past year PRME has reported negative net income.
  • PRME had a negative operating cash flow in the past year.
  • In the past 5 years PRME always reported negative net income.
  • PRME had a negative operating cash flow in each of the past 5 years.
PRME Yearly Net Income VS EBIT VS OCF VS FCFPRME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • With a Return On Assets value of -58.69%, PRME perfoms like the industry average, outperforming 42.58% of the companies in the same industry.
  • PRME has a Return On Equity of -166.41%. This is in the lower half of the industry: PRME underperforms 66.47% of its industry peers.
Industry RankSector Rank
ROA -58.69%
ROE -166.41%
ROIC N/A
ROA(3y)-75.58%
ROA(5y)-65.43%
ROE(3y)-147.74%
ROE(5y)-112.99%
ROIC(3y)N/A
ROIC(5y)N/A
PRME Yearly ROA, ROE, ROICPRME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PRME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRME Yearly Profit, Operating, Gross MarginsPRME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PRME Health Analysis

2.1 Basic Checks

  • PRME does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PRME has been increased compared to 1 year ago.
  • Compared to 5 years ago, PRME has more shares outstanding
  • PRME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRME Yearly Shares OutstandingPRME Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
PRME Yearly Total Debt VS Total AssetsPRME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • PRME has an Altman-Z score of -3.34. This is a bad value and indicates that PRME is not financially healthy and even has some risk of bankruptcy.
  • PRME has a Altman-Z score (-3.34) which is comparable to the rest of the industry.
  • There is no outstanding debt for PRME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.34
ROIC/WACCN/A
WACC9.37%
PRME Yearly LT Debt VS Equity VS FCFPRME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 4.84 indicates that PRME has no problem at all paying its short term obligations.
  • PRME has a Current ratio of 4.84. This is comparable to the rest of the industry: PRME outperforms 54.14% of its industry peers.
  • A Quick Ratio of 4.84 indicates that PRME has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 4.84, PRME is in line with its industry, outperforming 55.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.84
Quick Ratio 4.84
PRME Yearly Current Assets VS Current LiabilitesPRME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. PRME Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.76% over the past year.
  • Looking at the last year, PRME shows a very strong growth in Revenue. The Revenue has grown by 55.28%.
  • Measured over the past years, PRME shows a decrease in Revenue. The Revenue has been decreasing by -2.32% on average per year.
EPS 1Y (TTM)15.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
Revenue 1Y (TTM)55.28%
Revenue growth 3YN/A
Revenue growth 5Y-2.32%
Sales Q2Q%-61.61%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.44% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 28.89% on average over the next years. This is a very strong growth
EPS Next Y31.23%
EPS Next 2Y16.48%
EPS Next 3Y11.23%
EPS Next 5Y8.44%
Revenue Next Year-24.37%
Revenue Next 2Y-13.03%
Revenue Next 3Y-35.37%
Revenue Next 5Y28.89%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PRME Yearly Revenue VS EstimatesPRME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
PRME Yearly EPS VS EstimatesPRME Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. PRME Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PRME. In the last year negative earnings were reported.
  • Also next year PRME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRME Price Earnings VS Forward Price EarningsPRME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRME Per share dataPRME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.48%
EPS Next 3Y11.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRME Dividend Analysis

5.1 Amount

  • No dividends for PRME!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRME Fundamentals: All Metrics, Ratios and Statistics

PRIME MEDICINE INC

NASDAQ:PRME (3/27/2026, 8:00:01 PM)

After market: 3.3646 -0.02 (-0.46%)

3.38

-0.26 (-7.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03
Earnings (Next)05-06
Inst Owners64.23%
Inst Owner Change-2.21%
Ins Owners11.36%
Ins Owner Change0%
Market Cap610.26M
Revenue(TTM)4.63M
Net Income(TTM)-201.14M
Analysts80
Price Target6.59 (94.97%)
Short Float %18.34%
Short Ratio8.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.69%
Min EPS beat(2)-24%
Max EPS beat(2)-1.38%
EPS beat(4)0
Avg EPS beat(4)-14.61%
Min EPS beat(4)-24%
Max EPS beat(4)-1.38%
EPS beat(8)2
Avg EPS beat(8)-6.01%
EPS beat(12)2
Avg EPS beat(12)-9.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-23.95%
Min Revenue beat(2)-64.89%
Max Revenue beat(2)17%
Revenue beat(4)2
Avg Revenue beat(4)-9.78%
Min Revenue beat(4)-64.89%
Max Revenue beat(4)35.89%
Revenue beat(8)4
Avg Revenue beat(8)83.06%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-3.9%
EPS NQ rev (3m)-3.9%
EPS NY rev (1m)0%
EPS NY rev (3m)1.31%
Revenue NQ rev (1m)32.9%
Revenue NQ rev (3m)66.13%
Revenue NY rev (1m)-17.3%
Revenue NY rev (3m)-6.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 131.75
P/FCF N/A
P/OCF N/A
P/B 5.05
P/tB 5.05
EV/EBITDA N/A
EPS(TTM)-1.39
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0.03
BVpS0.67
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -58.69%
ROE -166.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.58%
ROA(5y)-65.43%
ROE(3y)-147.74%
ROE(5y)-112.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.89%
Cap/Sales 97.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.84
Quick Ratio 4.84
Altman-Z -3.34
F-Score5
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)122.8%
Cap/Depr(5y)364.34%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
EPS Next Y31.23%
EPS Next 2Y16.48%
EPS Next 3Y11.23%
EPS Next 5Y8.44%
Revenue 1Y (TTM)55.28%
Revenue growth 3YN/A
Revenue growth 5Y-2.32%
Sales Q2Q%-61.61%
Revenue Next Year-24.37%
Revenue Next 2Y-13.03%
Revenue Next 3Y-35.37%
Revenue Next 5Y28.89%
EBIT growth 1Y-2.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.42%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.31%
OCF growth 3YN/A
OCF growth 5YN/A

PRIME MEDICINE INC / PRME Fundamental Analysis FAQ

What is the fundamental rating for PRME stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRME.


What is the valuation status of PRIME MEDICINE INC (PRME) stock?

ChartMill assigns a valuation rating of 0 / 10 to PRIME MEDICINE INC (PRME). This can be considered as Overvalued.


What is the profitability of PRME stock?

PRIME MEDICINE INC (PRME) has a profitability rating of 0 / 10.


What is the earnings growth outlook for PRIME MEDICINE INC?

The Earnings per Share (EPS) of PRIME MEDICINE INC (PRME) is expected to grow by 31.23% in the next year.